Roberts N B, Williams P
Department of Chemical Pathology, Royal Liverpool Hospital, UK.
Ann Clin Biochem. 1988 Mar;25 ( Pt 2):169-75. doi: 10.1177/000456328802500207.
A serum aluminium assay has been established using a DC plasma emission spectrometer and calibration with serum based standards. The assay is linear between 0.20 and 18.0 mumol/L aluminium. The procedure gives good analytical recovery and precision. The assay was validated by comparison(s) with an electrothermal atomic absorption (ETAAS) procedure which showed good agreement. Serum aluminium concentrations have been compared in normal individuals, in undialysed chronic renal failure patients with or without aluminium hydroxide treatment, and in dialysed patients treated with oral aluminium hydroxide. Non-dialysed patients had higher serum aluminium concentrations if treated with aluminium hydroxide. Haemodialysis patients had the highest serum aluminium concentrations whilst those on peritoneal dialysis had levels similar to those of the non-dialysed chronic renal failure group.
已使用直流等离子体发射光谱仪并采用基于血清的标准品进行校准,建立了血清铝测定法。该测定法在铝浓度为0.20至18.0 μmol/L之间呈线性。该方法具有良好的分析回收率和精密度。通过与电热原子吸收光谱法(ETAAS)进行比较验证了该测定法,结果显示两者具有良好的一致性。比较了正常个体、未接受透析的慢性肾衰竭患者(无论是否接受氢氧化铝治疗)以及接受口服氢氧化铝治疗的透析患者的血清铝浓度。未接受透析的患者若接受氢氧化铝治疗,其血清铝浓度较高。血液透析患者的血清铝浓度最高,而腹膜透析患者的血清铝浓度与未接受透析的慢性肾衰竭组相似。